Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Connect Biopharma Holdings Limited Sponsored ADR (CNTB) vs Spero Therapeutics, Inc. (SPRO)

Connect Biopharma Holdings Limited Sponsored ADR and Spero Therapeutics, Inc. are both Biotechnology companies. Connect Biopharma Holdings Limited Sponsored ADR and Spero Therapeutics, Inc. are of similar size ($71.6M and $69.3M). Connect Biopharma Holdings Limited Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 8.8×. Spero Therapeutics, Inc. has the higher net margin (0.00% vs −2,298.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Spero Therapeutics, Inc. leads on 14 and Connect Biopharma Holdings Limited Sponsored ADR on 0.

Valuation

Metric CNTB SPRO Biotechnology median
P/E n/m 8.79 7.88
P/S 22.63 1.17 11.47
P/B 2.53 1.61 2.52
Price to free cash flow n/m 3.65 21.16
EV/EBITDA n/m 3.41 0.74
EV/Sales 12.21 0.34 10.73
Earnings yield (110.19%) 11.38% (28.84%)
Free cash flow yield (89.84%) 27.41% (23.03%)

Profitability

Metric CNTB SPRO Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (2,346.35%) 0.00% 0.00%
Net margin (2,298.93%) 0.00% 0.00%
Free cash flow margin (2,018.76%) 0.00% 0.00%
Return on equity (140.51%) 19.17% (57.72%)
Return on assets (109.34%) 12.85% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CNTB SPRO Biotechnology median
Revenue growth (TTM) — 37.24% 5.64%
EPS growth (last fiscal year) (257.14%) 111.81% —
Revenue growth, 5-year CAGR — 48.25% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CNTB SPRO Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 2.37 6.12 4.73
Net debt to EBITDA 0.77 (6.38) 0.96

Dividend

Metric CNTB SPRO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CNTB SPRO Biotechnology median
Market cap 69.27m 71.63m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack